Tempest Therapeutics (TPST) Competitors $0.50 -0.01 (-1.03%) Closing price 04:00 PM EasternExtended Trading$0.49 -0.01 (-1.92%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. OGI, TLSA, GLSI, DERM, MCRB, ALEC, ENTA, EPRX, LXEO, and ZNTLShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Organigram (OGI), Tiziana Life Sciences (TLSA), Greenwich LifeSciences (GLSI), Journey Medical (DERM), Seres Therapeutics (MCRB), Alector (ALEC), Enanta Pharmaceuticals (ENTA), Eupraxia Pharmaceuticals (EPRX), Lexeo Therapeutics (LXEO), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Organigram Tiziana Life Sciences Greenwich LifeSciences Journey Medical Seres Therapeutics Alector Enanta Pharmaceuticals Eupraxia Pharmaceuticals Lexeo Therapeutics Zentalis Pharmaceuticals Organigram (NASDAQ:OGI) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation. Does the MarketBeat Community believe in OGI or TPST? Organigram received 96 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 70.71% of users gave Organigram an outperform vote while only 66.23% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Tempest TherapeuticsOutperform Votes10266.23% Underperform Votes5233.77% Is OGI or TPST more profitable? Tempest Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -31.69%. Organigram's return on equity of -8.59% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organigram-31.69% -8.59% -6.54% Tempest Therapeutics N/A -187.44%-82.61% Do analysts prefer OGI or TPST? Tempest Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 1,609.40%. Given Tempest Therapeutics' higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of OGI or TPST? 34.6% of Organigram shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 0.1% of Organigram shares are held by company insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, OGI or TPST? Organigram has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.34, suggesting that its stock price is 334% less volatile than the S&P 500. Which has better valuation & earnings, OGI or TPST? Tempest Therapeutics has lower revenue, but higher earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram$166.12M0.72-$33.39M-$0.38-2.48Tempest TherapeuticsN/AN/A-$29.49M-$1.50-0.36 Does the media prefer OGI or TPST? In the previous week, Organigram had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Organigram and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.86 beat Organigram's score of 0.03 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Organigram Neutral Tempest Therapeutics Positive SummaryOrganigram beats Tempest Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.88M$6.24B$5.22B$7.23BDividend YieldN/A2.87%5.00%4.20%P/E Ratio-0.366.8020.8717.56Price / SalesN/A195.55356.6189.59Price / CashN/A65.6738.1534.64Price / Book0.395.546.213.83Net Income-$29.49M$141.14M$3.19B$247.27M7 Day Performance-23.59%-7.15%-5.21%-5.93%1 Month Performance-34.67%-16.94%-4.60%-10.15%1 Year Performance-86.32%-19.18%2.11%-7.96% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics3.0003 of 5 stars$0.50-1.0%$9.33+1,764.4%-86.4%$22.77MN/A-0.3320OGIOrganigram0.6368 of 5 stars$1.01-1.9%N/A-56.4%$127.52M$166.12M-2.66860Gap UpTLSATiziana Life Sciences0.4953 of 5 stars$1.08-3.6%N/A+99.8%$126.20MN/A0.008GLSIGreenwich LifeSciences1.783 of 5 stars$9.54-6.7%$38.00+298.3%-44.8%$125.40MN/A-11.923News CoverageGap UpDERMJourney Medical2.1938 of 5 stars$5.90-3.4%$9.67+63.8%+89.1%$123.25M$56.13M-6.2890MCRBSeres Therapeutics2.4647 of 5 stars$0.70-2.9%$4.00+471.3%-24.9%$122.07M$126.33M-3.04330Gap UpALECAlector3.4958 of 5 stars$1.23-4.7%$3.50+184.6%-82.7%$121.88M$100.56M-0.72270Gap UpENTAEnanta Pharmaceuticals4.0276 of 5 stars$5.52-3.3%$17.25+212.5%-71.9%$117.76M$66.59M-1.12160News CoverageGap UpEPRXEupraxia Pharmaceuticals1.7538 of 5 stars$3.28-3.1%$10.50+220.6%N/A$116.74MN/A-4.5529Gap DownLXEOLexeo Therapeutics3.1581 of 5 stars$3.47-15.4%$22.80+557.1%-86.2%$115.19M$650,000.00-1.1058Analyst ForecastNews CoverageGap UpZNTLZentalis Pharmaceuticals1.469 of 5 stars$1.59-12.2%$8.24+418.5%-92.3%$114.18M$67.43M-0.64160Gap Up Remove Ads Related Companies and Tools Related Companies OGI Alternatives TLSA Alternatives GLSI Alternatives DERM Alternatives MCRB Alternatives ALEC Alternatives ENTA Alternatives EPRX Alternatives LXEO Alternatives ZNTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt Discover why Notable Names ...Huge Alerts | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | SponsoredFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” ...Colonial Metals | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TPST Stock Free TPST Stock Alerts